文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

英格兰HIV感染者侵袭性肺炎球菌疾病1999-2017年流行病学

Invasive Pneumococcal Disease in People With Human Immunodeficiency Virus in England, 1999-2017.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究将英格兰HIV成人队列与确诊侵袭性肺炎球菌疾病(IPD)病例链接,分析1999-2017年IPD发病率变化。PCV13引入后HIV感染者IPD发病率下降并趋稳,但病毒抑制者仍高于一般人群,提示应继续对IPD患者检测HIV。

要点

  • HIV感染者IPD发病率在PCV13引入后下降并稳定于92-113/10万。
  • 2014-2017年接受抗逆转录病毒治疗者IPD发病率显著低于未治疗者。
  • 病毒抑制者IPD发病率仍为一般人群的4.5倍,需持续监测。

核心结论

  • PCV13引入后HIV感染者IPD发病率下降并保持稳定。
  • 应继续对表现为IPD的成人进行HIV检测。

研究设计与样本

  • 全国HIV成人队列与1999-2017年确诊IPD病例链接分析。

主要发现

  • HIV感染者IPD发病率从1999年147/10万升至2007年284/10万,2014-2017年稳定在92-113/10万。
  • 2014-2017年接受抗逆转录病毒治疗者年均IPD发病率为68/10万,未治疗者为720/10万(IRR 9.3,95%CI 7.3-11.8,P<.001)。
  • 病毒抑制者年均IPD发病率为50/10万,未抑制者为523/10万(IRR 10.4,95%CI 7.6-14.1,P<.001)。
  • 病毒抑制者IPD发病率仍为一般人群(11.2/10万)的4.5倍(95%CI 3.8-5.3,P<.001)。
  • 24%(345/1453)的IPD与HIV在90天内同时诊断,6%(89/1453)存在更早诊断HIV的机会。

临床怎么用

  • 对表现为IPD的成人应继续检测HIV感染。
  • HIV感染者应接受抗逆转录病毒治疗并维持病毒抑制以降低IPD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 7-valent and 13-valent pneumococcal conjugate vaccines (PCVs) were introduced into the UK childhood immunization program in 2006 and 2010, respectively, with high effectiveness and resulting in both direct and indirect protection. We describe the epidemiology of invasive pneumococcal disease (IPD) in adults with human immunodeficiency virus (HIV) in England following the introduction of both PCVs. METHODS: Data on a national cohort of people with HIV were linked to confirmed IPD cases in adults aged ≥ 15 years during 1999-2017. Date of HIV infection was estimated using a CD4 slope decline algorithm. RESULTS: Among 133 994 adults with HIV, 1453 developed IPD during 1999-2017, with 70% (1016/1453) developing IPD ≥ 3 months after their HIV diagnosis. IPD and HIV were codiagnosed within 90 days in 345 (24%) individuals. A missed opportunity for earlier HIV diagnosis was identified in 6% (89/1453), mostly in earlier years. IPD incidence in people with HIV increased from 147/100 000 in 1999 to 284/100 000 in 2007 before declining and stabilizing between 92 and 113/100 000 during 2014-2017. Mean annual IPD incidence was lower among those receiving antiretroviral therapy during 2014-17 (68 vs 720/100 000; incidence rate ratio [IRR] 9.3; 95% confidence interval [CI], 7.3-11.8; P < .001) and was markedly lower in those with a suppressed viral load (50 vs 523/100 000; IRR 10.4; 95% CI, 7.6-14.1; P < .001). The latter group still had 4.5-fold higher (95% CI, 3.8-5.3; P < .001) IPD incidence compared to the general population (11.2/100 000). CONCLUSIONS: IPD incidence among people with HIV reduced after PCV13 introduction and has remained stable. Adults presenting with IPD should continue to be tested for HIV infection.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kirwan PD, Amin-Chowdhury Z, Croxford SE, et al. Invasive Pneumococcal Disease in People With Human Immunodeficiency Virus in England, 1999-2017. Clin Infect Dis. 2021. PMID: 32789498. doi:10.1093/cid/ciaa522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。